DEAR DR. ROACH: My 28-year-old son is in the hospital. He hasn’t been acting like himself for a few weeks (not sleeping nor eating well), and he suddenly had four seizures. The doctors are worried ...

DEAR DR. ROACH: My 28-year-old son is in the hospital. He hasn’t been acting like himself for a few weeks (not sleeping nor eating well), and he suddenly had four seizures. The doctors are worried ...

Scientists at KAIST have found a way to turn a tumor’s own immune cells into powerful cancer fighters—right inside the body. Tumors are packed with macrophages, immune cells that should attack cancer ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer. Rather than targeting cancer cells ...

Bristol Myers Squibb hasn’t had much luck with its efforts to develop cancer treatments called T cell engagers. But the pharmaceutical company isn’t done pursuing this type of targeted cancer therapy, ...

Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic. The resulting candidate ...

A new approach to tumor defenses In a strategy modeled after the famed Trojan horse, the treatment enters the tumors by targeting cells called macrophages that guard the cancer cells, disarms these ...

Diffuse intrinsic pontine glioma (DIPG) is one of the most devastating pediatric brain tumors. It sits in the brainstem where it cannot be surgically removed, responds poorly to chemotherapy, and ...

Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable to perform their roles properly due to suppression by the tumor. A KAIST ...

Scientists at UCLA have developed an “off-the-shelf” cell-based immunotherapy that was able to track down and kill pancreatic cancer cells even after they had spread to other organs. In a mouse study, ...